Genetic Engineering & Biotechnology News

SEP15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 28 of 77

Genetic Engineering & Biotechnology News | | SEPTEMBER 15, 2017 | 27 tween different types of cells using machine learning. These steps can be combined into bespoke algorithms for a wide range of ap- plications, complemented by extensive visu- alization and annotation tools." Ultimately, Dr. Bankhead hopes that re- searchers might choose to build on QuPath's extensibility and user-friendliness, making their algorithms accessible to all. "Achieving this relies primarily on establishing an ac- tive community of users and developers," he insists. "This community-driven model has proven enormously successful for bioimage analysis, through the widespread adoption of open-source software such as ImageJ and Fiji. I would be very happy if QuPath might contribute to a similar move toward greater openness and reproducibility in the field of digital pathology." Pathologist-Friendly Integration As tests become more sophisticated and generate data more comprehensive, the re- sulting information explosion requires seam- less integration for efficient data manage- ment, querying, and mining. No small task. "The development of a multisite pathology informatics platform must encompass many key elements," reports Sylvia Asa, M.D., Ph.D., professor, department of laboratory medicine and pathobiology, University of Toronto, Canada, and former pathologist-in- chief at University Health Network (UHN). She continues, "At UHN, we engaged a team of physicians, informatics personnel, and engineers, among others, to build a pa- thologist-friendly platform for pathology in- formatics. This encompasses a sophisticated laboratory information system and whole- slide imaging for histology and immunohis- tochemistry that is integrated with electron microscopic images and data captured from flow cytometers, etc. Further, we also inte- grated cytogenetics analyses and molecular diagnostics." Accomplishing this task within a cam- pus setting was one aspect, but extending it to locations in a healthcare system that encompassed a large geographic area was a separate challenge. "This platform allows reporting of every specimen by the right pa- thologist at the right time. Integration also facilitates participation by pathologists in multidisciplinary case conferences and vir- tual presentations in varied locations. Ulti- mately, we want to ensure that the patholo- gist has the greatest level of access to the best data and gives the most accurate informa- tion for high-quality personalized and preci- sion medicine." The electronic approach reemphasizes the critical role of pathology as the basis of diag- nostic medicine, a status it secured more than a century ago. Recalling a paper written by Sir William Osler and published in a 1909 issue of the British Medical Journal, Dr. Asa offers the following quotation: "As is our pathol- The Next Evolution For the past 75 years, Kerry has evolved with the market trends in cell culture. As our customers' needs changed we have expanded our product portfolio to encompass technologies needed to meet the evolving needs of the bio-pharma market globally. AmpliCHO CD medium is our latest evolution. AmpliCHO CD medium is a completely chemical chemically-defi ned medium that does not contain supplements. It is optimized for extended growth and enhanced recombinant protein production for CHO suspension cultures. The benefi ts of using AmpliCHO CD medium: ● Signifi cantly higher titers ● Low osmolality ● Extended viable density and cell viability ● Animal component free (ACF) ● Compatible with complex, defined, and CD supplements and feed Chemically Defi ned Medium | Supplement Systems | Defi ned Supplements | Hydrolyzed Proteins | Yeast Extracts Learn more at Sheffi See Tissue Samples on page 28 Translational Medicine Digital pathology may advance the development of cancer drugs such as checkpoint inhibitors by processing images that inform tumor profiling, mechanisms of action, and patient selection. For example, automated image analysis algorithms are being used to augment immunohistochemistry (IHC) testing in the clinic. In this image from Bristol-Myers Squibb, PD-L1 IHC testing of formalin-fixed paraffin- embedded lung tissue shows a staining pattern that reflects non-small cell lung carcinoma. " The idea is to take routinely acquired data and maximize knowledge gleaned using computational tools." —Dr. Anant Madabhushi

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP15 2017